Insider Transactions in Q2 2025 at Pacira Bio Sciences, Inc. (PCRX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Laura Brege Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+20.63%
|
-
|
|
Jun 11
2025
|
Alethia Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+35.1%
|
-
|
|
Jun 11
2025
|
Christopher Christie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+27.01%
|
-
|
|
Jun 11
2025
|
Michael J. Yang Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+31.51%
|
-
|
|
Jun 11
2025
|
Marcelo Bigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+27.43%
|
-
|
|
Jun 11
2025
|
Mark Froimson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+23.0%
|
-
|
|
Jun 11
2025
|
Abraham Ceesay Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,163
+35.1%
|
-
|
|
Jun 11
2025
|
Mark A. Kronenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,999
+22.27%
|
-
|
|
Jun 04
2025
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
5,578
-8.56%
|
$145,028
$26.21 P/Share
|
|
Jun 04
2025
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
14,376
-8.17%
|
$373,776
$26.24 P/Share
|
|
Jun 03
2025
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,374
-4.92%
|
$87,724
$26.4 P/Share
|
|
Jun 03
2025
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,084
-2.72%
|
$132,184
$26.4 P/Share
|
|
Jun 03
2025
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,162
-3.38%
|
$160,212
$26.4 P/Share
|